The historical rank and industry rank for Cyfuse Biomedical KK's Days Payable or its related term are showing as below:
TSE:4892'
s Days Payable Range Over the Past 10 Years
Min: 2.8 Med: 25.35 Max: 627.64
Current: 627.64
During the past 6 years, Cyfuse Biomedical KK's highest Days Payable was 627.64. The lowest was 2.80. And the median was 25.35.
TSE:4892's Days Payable is ranked better than 95.44% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.61
vs TSE:4892: 627.64
Cyfuse Biomedical KK's Days Payable
declined
from Jun. 2024 (30.94) to Dec. 2025 (0.00).
It may suggest that Cyfuse Biomedical KKaccelerated paying its suppliers.
Cyfuse Biomedical KK Days Payable Related Terms
Cyfuse Biomedical KK Days Payable Historical Data
* Premium members only.
The historical data trend for Cyfuse Biomedical KK's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyfuse Biomedical KK Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's Days Payable distribution charts can be found below:
* The bar in red indicates where Cyfuse Biomedical KK's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cyfuse Biomedical KK's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyfuse Biomedical KK (TSE:4892) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cyfuse Biomedical KK and its competitors. Over the past decade, Cyfuse Biomedical KK's Days Payable has ranged from 2.80 to 627.64. According to the industry distribution chart, Cyfuse Biomedical KK ranks #42 out of 922 companies in the Drug Manufacturers industry, placing it in the top 4.6%.
Is Cyfuse Biomedical KK's Days Payable too high?
Cyfuse Biomedical KK's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 2.80 to a high of 627.64. Based on the distribution chart, Cyfuse Biomedical KK ranks #42 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cyfuse Biomedical KK has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cyfuse Biomedical KK ranks #42 out of 922 companies for Days Payable. This places Cyfuse Biomedical KK in the top 5% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.61. Historically, Cyfuse Biomedical KK's own Days Payable has ranged from 2.80 to 627.64 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.61, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cyfuse Biomedical KK and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyfuse Biomedical KK's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (TSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,950.43, compared to a current price of 円556.00 — trading 71.5% below its estimated fair value. The current Days Payable is 0.00. Cyfuse Biomedical KK's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cyfuse Biomedical KK (TSE:4892), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyfuse Biomedical KK (TSE:4892) Overvalued in 2026?
Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued.
The current stock price of 円556.00 is trading 71.5% below its estimated GF Value™ of 円1,950.43.
GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.
Key valuation signals for TSE:4892:
Days Payable: 0.00
GF Value™: 円1,950.43 vs. price of 円556.00 (71.5% below fair value)
No single metric tells the full story. See the TSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
53GF Score
Get the complete analysis for TSE:4892
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4892 has been successfully added to your 
